ASH Annual Meeting

Ciltacabtagene autoleucel continues to show promise for the treatment of relapsed or refractory multiple myeloma.

An early study showed that encouraging responses were elicited with olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

VITAL study results reveal survival advantage of birtamimab for patients with Mayo Stage IV amyloid light chain amyloidosis.

In the ECOG-ACRIN E1910 study, blinatumomab with consolidation chemotherapy extended overall survival in patients with MRD-negative B-cell acute lymphoblastic leukemia.

Clinical benefit has been achieved with zanubrutinib treatment in patients B-cell malignancies who were intolerant to acalabrutinib.

Phase 2 study results show the durability of response associated with mosunetuzumab in patients with relapsed or refractory follicular lymphoma.

In a final analysis of the DREAMM-2 study, results showed the rapid and durable responses of belantamab mafodotin continued in patients with relapsed/refractory multiple myeloma despite ocular toxicities.

Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.

Compared with standard of care regimens for triple-class exposed, relapsed or refractory multiple myeloma, belantamb mafodotin with pomalidomide and dexamethasone extended progression-free survival without sacrificing safety.

The phase 2 ELARA trial achieved durable responses in patients with relapsed/refractory follicular lymphoma who were treated with tisagenlecleucel.

In the phase 3 TRANSFORM study, lisocabtagene maraleucel bested standard of care as treatment of patients with high-risk relapsed/refractory large B-cell lymphoma.

The SINTRA-REV trial showed lower risk of transfusion dependency in patients with MDS treated with lenalidomide.

Rebecca Silbermann, MD, MMS, discusses the findings of the phase 2 GRIFFIN study which were presented at the 2022 ASH Annual Meeting.

Phase 3 TRIANGLE results show the efficacy of ibrutinib induction and ibrutinib maintenance in patients with mantle cell lymphoma.

Phase 1 data demonstrate that the combination of selinexor and ruxolitinib has the potential to be a novel first-line treatment for myelofibrosis patients, according to Haris Ali, MD.

Adding magrolimab to azacytidine and venetoclax led to a rate of high responses in high-risk de novo and secondary acute myeloid leukemia.

COMMODORE study results are positive for its two primary end points of stable hemolysis control and transfusion avoidance in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab.

The use of iberdomide alone or with anti-CD20 antibodies show efficacy in patients with relapsed or refractory lymphoma.

Christopher J. Melani, MD, discusses the combination regimen from the ViPOR study evaluating patients with aggressive lymphomas.

Positive results were shown with ziftomenib monotherapy in heavily pretreated patients with relapsed or refractory acute myeloid leukemia.

MAGNOLIA study results demonstrated that zanubrutinib maintained response in patients with relapsed/refractory marginal zone lymphoma.

Phase 1/2 BRUIN study results show high response rates in patients with Waldenström macroglobulinemia who were treated with pirtobrutinib.

Five-year follow up results from the phase 3 AUGMENT trial show that lenalidomide plus rituximab produced enhanced progression-free survival in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Olverembatinib is efficacious and well tolerated in tyrosine kinase inhibitor-resistant CML-CP and CML-AP patients with a BCR-ABL1 T315I mutation.

Comparing intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation to watchful waiting followed by sequential conditioning did not show superior results.

Salvage chemotherapy after lintuzumab-Ac225 showed promising early efficacy results in patients with relapsed/refractory acute myeloid leukemia by eliminating residual leukemia cells.

Joseph M. Scandura, MD, PhD, provides an overview on the research of pelabresib which will be discussed at the 2022 American Society of Hematology Annual Meeting.

Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

Liso-cel was found to improve quality of life in patients with large B-cell lymphoma compared with standard of care.

Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.